127 related articles for article (PubMed ID: 31930649)
1. Immunotherapy-related acute kidney injury: Kidney biopsy or not?
Chatterton S; Williams S; Nahar K; Menzies AM; Wong MG
Nephrology (Carlton); 2021 Jan; 26(1):89-90. PubMed ID: 31930649
[No Abstract] [Full Text] [Related]
2. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
3. [Histoseminar on inflammatory bowel diseases (IBD): Case n
Fléjou JF
Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
[No Abstract] [Full Text] [Related]
4. Nivolumab plus ipilimumab in metastatic colorectal cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e139. PubMed ID: 29395861
[No Abstract] [Full Text] [Related]
5. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
6. AKI in Patients Receiving Immune Checkpoint Inhibitors.
Perazella MA; Sprangers B
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
[No Abstract] [Full Text] [Related]
7. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
8. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
9. Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma.
Kubo T; Sugawara T; Shinkawa T; Kurisu T; Kouzen N; Tanaka T; Fukuta F; Yamasaki K; Sugita S; Matsuo K; Morita R; Hirohashi Y; Tsukahara T; Kanaseki T; Hasegawa T; Masumori N; Torigoe T
Immunol Med; 2021 Jun; 44(2):136-141. PubMed ID: 32634346
[TBL] [Abstract][Full Text] [Related]
10. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Zamarin D; Burger RA; Sill MW; Powell DJ; Lankes HA; Feldman MD; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann AR; Khleif S; Aghajanian C
J Clin Oncol; 2020 Jun; 38(16):1814-1823. PubMed ID: 32275468
[TBL] [Abstract][Full Text] [Related]
13. Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
Muhailan M; Al-Shbool G
Am J Med Sci; 2020 Jan; 359(1):e1-e2. PubMed ID: 31395282
[No Abstract] [Full Text] [Related]
14. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
15. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in colorectal cancer with mismatch repair deficiency.
Overman MJ
Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
[No Abstract] [Full Text] [Related]
19. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
